Rilonacept
- Generic Name
- Rilonacept
- Brand Names
- Arcalyst, 炎朵
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 501081-76-1
- Unique Ingredient Identifier
- 8K80YB5GMG
- Background
Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome (FCAS) and Muck...
- Indication
用于治疗成人及12岁青少年罕见病周期性综合征(CAPS),即家族性寒冷型自身炎症综合征和穆-韦（Muckle-Wells）两氏综合征。
- Associated Conditions
- Cryopyrin-associated Periodic Syndromes (CAPS), Deficiency of the interleukin-1 receptor antagonist, Familial Cold Autoinflammatory Syndrome (FCAS), Muckle-Wells Syndrome (MWS), Recurrent Pericarditis
- Associated Therapies
- -
Rilonacept in Diabetes Mellitus Type 1: Safety Study
- First Posted Date
- 2009-08-19
- Last Posted Date
- 2014-02-24
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 13
- Registration Number
- NCT00962026
- Locations
- 🇺🇸
Children's Medical Center, Dallas, Texas, United States
PREventative Study Against URate-Lowering Drug-Induced Gout Exacerbations (PRE-SURGE 2)
- First Posted Date
- 2009-08-13
- Last Posted Date
- 2017-04-28
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 248
- Registration Number
- NCT00958438
Inflammation in Chronic Kidney Disease and Cardiovascular Disease - The Role of Genetics and Interleukin-1 Receptor Antagonist (IL-1ra)
- Conditions
- Interventions
- First Posted Date
- 2009-05-12
- Last Posted Date
- 2019-10-01
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 15
- Registration Number
- NCT00897715
- Locations
- 🇺🇸
Tennessee Valley Healthcare System Nashville Campus, Nashville, TN, Nashville, Tennessee, United States
🇺🇸Vanderbilt University, Nashville, Tennessee, United States
Study Utilizing Rilonacept in Gout Exacerbations
- Conditions
- Interventions
- First Posted Date
- 2009-03-05
- Last Posted Date
- 2017-04-28
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 225
- Registration Number
- NCT00855920
Study of the Safety and Effectiveness of Rilonacept (IL-1 Trap) Administered Subcutaneously in Subjects With Non Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) and Anemia
- First Posted Date
- 2008-02-07
- Last Posted Date
- 2011-04-19
- Lead Sponsor
- Regeneron Pharmaceuticals
- Registration Number
- NCT00609544
Rilonacept for Treatment of Familial Mediterranean Fever (FMF)
- First Posted Date
- 2007-12-28
- Last Posted Date
- 2013-02-11
- Lead Sponsor
- The Cleveland Clinic
- Target Recruit Count
- 14
- Registration Number
- NCT00582907
- Locations
- 🇺🇸
NYU Hospital for Joint Diseases, New York, New York, United States
🇺🇸Children's Hospital of Central California, Madera, California, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
Rilonacept to Improve Artery Function in Patients With Atherosclerosis
- Conditions
- Interventions
- First Posted Date
- 2007-01-01
- Last Posted Date
- 2012-04-30
- Target Recruit Count
- 10
- Registration Number
- NCT00417417
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Interleukin-1 Trap to Treat Autoinflammatory Diseases
- Conditions
- Interventions
- First Posted Date
- 2004-10-28
- Last Posted Date
- 2014-03-04
- Target Recruit Count
- 11
- Registration Number
- NCT00094900
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.